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Abstract
Purpose—A large body of evidence suggests that being diagnosed with and treated for cancer
adversely affects functioning and quality of life, yet less is known about longer term outcomes.
Therefore, this study aims to estimate the prevalence of post-traumatic stress disorder (PTSD)
symptoms in survivors of adult non-Hodgkin’s lymphoma (NHL) who are at least 2 years
postdiagnosis and identify the risk factors associated with PTSD symptoms, with a focus on those
that are amenable for screening and modifiable.
Patients and Methods—A total of 886 NHL survivors identified from the cancer registries of
two hospitals in North Carolina participated, ranging in age from 25 to 92 years old and ranging
from 2 to 44 years postdiagnosis. Survivors were mailed a survey that assessed PTSD symptoms
and quality of life.
Results—Participants averaged 10.2 years postdiagnosis, and most (61%) reported no PTSD
symptoms. The adjusted prevalence for full PTSD was 7.9%, with an additional 9.1% meeting
criteria for partial PTSD. Modifiable risk factors that were independently associated with PTSD in
multiple linear regression included less social support, negative appraisals of life threat and
treatment intensity, and more employment and insurance issues. Additionally, several
demographic characteristics (nonwhite race, less education, and younger age) and clinical or
health-related factors (active disease, more recent diagnosis, and more comorbidity) were
independently associated with PTSD.
Conclusion—Although only 8% of survivors met PTSD diagnostic criteria, the impact of a
cancer diagnosis and treatment persists for many survivors, as evidenced in 39% of this sample.
Early identification of those at risk could enable treatment to minimize PTSD symptomatology.
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A growing body of evidence suggests that the experience of being diagnosed with and
treated for cancer, regardless of age, adversely affects functioning and quality of life.
However, less is known about the longer term effects (2 years after diagnosis and beyond) of
cancer on survivors’ well-being, especially adults with cancer other than breast cancer. Of
note, little is known about the needs of individuals diagnosed with non-Hodgkin’s
lymphoma (NHL), which is the sixth most common cancer in the United States and has an
overall 5-year survival rate of 63%.
NHL incidence rates have doubled since the early 1970s, an increase that is only partially
explained by AIDS-related NHL. The lifetime risk for developing NHL is approximately
one in 50, with older adults (median age of 66 years) at highest risk.1 Consequently, and
because the number of survivors in the United States is rapidly increasing as a result of both
medical advances that treat other conditions and the aging of the population, health care
teams would benefit from evidence regarding the needs of NHL survivors. If indicated,
interventions could be provided to improve their well-being.
Post-traumatic stress disorder (PTSD) is a set of symptoms (re-experiencing, avoidance, and
arousal) following direct exposure to a traumatic stressor where the individual is involved
in, witnesses, or learns about threatened death or serious injury. Symptoms of PTSD, such as
re-experiencing distressing events, avoiding cancer-related experiences, and physiologic
arousal, have been reported by breast cancer survivors, with prevalence estimates ranging
from 5% to 6%.2-5 Unfortunately, little data are available regarding PTSD in other adult
cancers. A conceptual modelfor cancer-related PTSD is illustrated in Figure 1, in which the
cancer diagnosis and associated events such as treatment and general health status are
conceptualized as stressors. Demographic characteristics and psychosocial resources relate
to the stressors, and these three sets of variables can directly or indirectly influence PTSD.
This model is based on the stress, appraisal, and coping theory of Lazarus and Folkman,6
which emphasizes the relationship between the person (his/her characteristics) and his/her
environment (cancer experience). Of note, cancer-related PTSD differs from more
traditional traumas in that the intrusions tend to be future-oriented fears, such as concerning
recurrence or treatment. The model reflects risk factors identified in previous studies of
adult cancer survivors, including younger age,7 female gender and negative perceptions of
treatment intensity,8 lower income,2 less social support and education,3 and less time since
treatment and advanced disease.4 This article presents prevalence estimates and risk factors
for PTSD, with a particular focus on potentially modifiable factors.
PATIENTS AND METHODS
Participants and Procedures
Potential study participants were identified through tumor registries at the Duke and
University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Centers.
Patients were eligible if they were diagnosed with NHL, were at least 19 years old at
diagnosis, and were at least 2 years postdiagnosis, whether or not they had currently active
disease. Each patient’s physician granted approval before the researchers requested patient
participation. Approval for all procedures was granted by the Institutional Review Boards at
the University of North Carolina and Duke University Schools of Medicine. On the basis of
the method for mailed surveys of Dillman,9 prospective participants were sent a brief
prenotice letter, a self-administered questionnaire with a $2 bill incentive and other study-
related materials, and thank you/reminder postcards. Nonrespondents were sent
replacements and later telephoned to confirm receipt of the mailed survey packet.
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Demographic and clinical characteristics—Self-reported participant demographic
information included birth date, sex, race, ethnicity, marital status, income, and education.
Details regarding diagnosis and treatment were obtained from Tumor Registry databases.
Histology was categorized as indolent or aggressive based on the updated Revised European
American Lymphoma/WHO classification system.10
Health status—The Self-Administered Comorbidity Questionnaire, a 12-item self-report
version of the Charlson Index, was used to assess other health-related problems.11 An
individual can receive up to 3 points for each of 12 medical conditions (1 point each for
presence of the problem, current treatment, and functional limitation). Selected questions
related to health care use and secondary cancer status were adapted from the Childhood
Cancer Survivor Study survey, a large epidemiologic study of long-term survivors of
childhood cancer.12
Psychosocial—Perceived availability of social support was assessed using the 20-item
Medical Outcomes Study–Social Support Survey.13 It has been used in various populations,
including long-term breast cancer survivors.3,14 The standardized score ranges from 20 to
100 and yielded an α = .97 in this study. The Appraisal of Life Threat and Treatment
Intensity Questionnaire assesses the extent to which cancer and its treatment are perceived to
be life threatening and intense in the past and currently.15 Its six items sum to a score
ranging from 6 to 30 and yielded an α = .80 in the present study. Finally, to assess
employment and insurance-related situations and difficulties, 24 items (possible score range,
0 to 24; α = .82) were derived from an instrument developed by the Cancer and Leukemia
Group B clinical research group.16 Examples include “I did not change jobs for fear of
losing health insurance” and “I was encouraged to leave my job” because of the cancer.
Post-traumatic stress—The PTSD Checklist–Civilian Version (PCL-C) assesses
symptomatology in noncombat populations by presenting a self-report symptom checklist
that closely mirrors criteria set forth by the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition for a formal diagnosis of PTSD.17,18 The instructions were
modified so that symptoms were keyed to the particular traumatic stressor of interest;
specifically, survivors were asked to rate each PTSD symptom in the past 4 weeks with
respect to their diagnosis and treatment for lymphoma. Each of 17 symptoms is rated with
respect to intensity on a scale of 1 (not at all) to 5 (extremely bothersome), and item scores
are summed to create a total that can range from 17 to 85 points. The following two
approaches were used to identify PTSD: (1) the cutoff method, in which those with scores ≥
44 are classified as having PTSD19; and (2) the symptom cluster method, which follows the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for PTSD in
that individuals who report having been at least moderately bothered by (score ≥ 3) one or
more re-experiencing symptoms (of five symptoms; eg, nightmares), three or more
avoidance symptoms (of seven symptoms; eg, evading follow-ups), and two or more arousal
symptoms (of five symptoms; eg, easily startled) are classified as having PTSD.17 Using the
PCL-C cutoff of 44, Blanchard et al19 reported a sensitivity of 0.94 and specificity of 0.86
with the Clinician Administered PTSD Scale. In other work, the PCL-C demonstrated an α
= .97, test-retest reliability of 0.96, and convergent validity of 0.93 with the Mississippi
Scale in a sample of 123 Vietnam veterans.18 In this study, the total score yielded an α = .91,
and the subscales produced the following internal consistency: re-experiencing, α = .88;
avoidance, α = .82; and arousal, α = .78.
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To assure that the PTSD prevalence estimates reflected the Tumor Registry sampling frame,
sample prevalence estimates were adjusted for nonresponse based on race (African
American or non-African American), as well as current age and age at diagnosis (in 20-year
increments). Although the data set overall had a small amount of missing data, the level of
missingness in three variables, namely income (10.6%), stage (13.5%), and disease status
(10.9%), justified multiple imputation via the Markov chain Monte Carlo algorithm.20 All
variables in the conceptual model were included in the Markov chain Monte Carlo
algorithm, but imputed values for the outcome variable (PCL-C) were not generated.
Twenty data sets containing imputed values were used in the multiple linear and logistic
regression analyses, and SEs adjusted for imputation were estimated in the SAS
MIANALYZE procedure (SAS Institute, Cary, NC).21 Bivariate analyses compared mean
levels of PCL-C for those with and without a given potential risk factor using t tests and
analysis of variance. Pearson correlations were calculated between the PCL-C and all
continuous independent variables. Multiple linear regression was used to estimate the
independent associations between candidate variables and the continuous PCL-C score;
logistic regression was used to estimate the associations of the same variables with meeting
criteria for full or partial PTSD, as defined by the symptom cluster method. Variables were
selected for inclusion in the multivariable models if they were at least marginally significant
(P<.10) in bivariate analyses. Data management and bivariate analyses were carried out with
SPSS Version 14.0 (SPSS Inc, Chicago, IL). Multiple imputation and multivariable analyses
were conducted using SAS Version 9.1.3 (SAS Institute).
RESULTS
Of the 1,312 eligible survivors who were mailed a survey, 117 (9%) of the packages were
returned undelivered, and tracing attempts were unsuccessful. Of the remaining 1,195
survivors who were assumed to have received a survey, 886 (74%) completed and returned
their surveys, 258 (22%) did not respond, and 51 (4%) refused participation. Sample bias
analyses using demographic information from the registries indicated that participating
survivors, compared with nonparticipants, were less frequently African American (10% v
20%, respectively; P<.001), older at study enrollment (mean age, 62.9 v 58.8 years,
respectively; P<.001), and older at diagnosis (52.6 v 48.1 year, respectively; P<.001). The
868 survivors who completed the PCL-C were included in further analyses.
The sample characteristics are listed in Table 1. A similar number of females and males
participated, 14% were nonwhite, 25% earned less than $30,000 annually, 38% had a
college degree, and 40% were employed. Mean age at study enrollment was 63 years, and
almost half of participants (46%) were older adults (≥ 65 years of age). The majority of
participants reported having received chemotherapy treatment (78%) and that they were not
currently in treatment for NHL (85%). The mean age at lymphoma diagnosis was 53 years
(range, 19 to 87 years). The mean interval from diagnosis to study enrollment was 10.2
years (range, 2 to 44 years). Having received a second primary cancer diagnosis was cited
by 14% of the sample, and 4% were currently receiving treatment for it. Participants cited an
average of 2.9 comorbid conditions (standard deviation [SD], 2.1 comorbidities; range, 0 to
12 comorbidities), primarily back pain (42%), high blood pressure (40%), and heart disease
(26%), and 1% had AIDS-related NHL. Scores on the psychosocial variables were as
follows: for social support, 83.1 (SD, 16.4; range, 20 to 100); appraisal of life threat, 19.3
(SD, 6.0; range, 6 to 30); and cancer-related employment and insurance issues, 1.1 (SD, 2.1;
range, 0 to 17).
The overall mean PCL-C score in this sample was 27.0 (SD, 9.9), with subscale scores of
6.9 (SD, 3.1) for re-experiencing, 9.3 (SD, 3.8) for arousal, and 10.8 (SD, 4.4) for
Smith et al. Page 4













avoidance. As shown in Table 2, the prevalence of cancer-related PTSD in the sample was
similar using the cutoff score (6.9%) and symptom cluster (7.6%) methods. After applying
weights to account for nonresponse bias, the adjusted prevalence rose to 7.4% and 7.9% for
each of these methods. Seventeen percent rated at least two of the three PTSD symptom
clusters (partial or full PTSD) as occurring moderately to extremely often. Across the
symptom clusters, 30% met the criteria for arousal, 20% met criteria for re-experiencing,
and 14% met criteria for avoidance. Overall, 39% met criteria for at least one PTSD
symptom cluster.
Relationship of PTSD Symptoms to Other Variables
Bivariate associations between PCL-C scores and the independent variables are listed in
Table 3. Among demographic and clinical variables, those who were nonwhite, had an
annual income under $30,000, did not obtain a college degree, were younger, received a
bone marrow or stem-cell transplantation, received biologic treatment, were currently
receiving treatment for NHL, had active disease, and experienced at least one NHL
recurrence had higher PCL-C scores (all P ≤ .01). Among the continuous variables, the
strongest PCL-C relationships (all P<.001) were for comorbidity (r = 0.27), social support (r
= −0.36), appraisal of life threat and treatment intensity (r = 0.37), and cancer-related
insurance and employment issues (r = 0.27). In addition, significant PCL-C associations
were found for age at study enrollment (r = −0.15), initial stage of disease (r = 0.11), sum of
treatment types (r = 0.13), number of NHL-related visits to a physician (r = 0.19), age at
diagnosis (r = −0.08), time since diagnosis (r = −0.11), and time since last physical
examination (r = 0.08).
Regression Analyses
Table 4 lists the results of a multiple linear regression for the PCL-C score and logistic
regression for partial or full PTSD (ie, at least two symptom clusters) for those variables at
least marginally significant in the bivariate analyses (P<.10). Nonwhite race, less education,
younger age at enrollment, having active NHL disease, less time since diagnosis, more
comorbidity, less social support, more negative appraisals, and more insurance and
employment issues were independently associated with worse PCL-C scores. For example,
survivors with active disease had PCL-C scores 3.7 points higher than those in remission or
cured (P = .001). Furthermore, survivors of nonwhite race had PCL-C scores 2.4 points
higher than those of white race (P = .004). The full model accounted for 38.5% of the
variance (P<.001).
In the logistic regression model, three risk factors (nonwhite race, younger age, and active
disease status) that were identified in the linear regression were not independently associated
with PTSD symptoms, although race remained marginally statistically significant (P = .07),
with nonwhite participants having 1.7 times greater odds of having partial or full PTSD than
white participants. Furthermore, when a logistic model for full PTSD (symptom clusters = 3;
7.9% of sample) was estimated, the odds ratio was 2.8 (95% CI, 1.4 to 5.8) for nonwhite
race and 4.3 (95% CI, 1.5 to 12.2) for active disease. Finally, education, time since
diagnosis, comorbidity, and all psychosocial variables (social support, appraisals, and
employment and insurance issues) had independent associations with PTSD symptoms.
DISCUSSION
This study is one of the first examinations of well-being among long-term survivors of NHL,
who report varying degrees of PTSD symptomatology. Although the prevalence in this
sample is somewhat lower than that found in some other traumatized populations, our
adjusted prevalence of 7.4% to 7.9% is more than three times the 2.4% prevalence in the
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general adult population.22,23 Although prevalence estimates are highly dependent on the
methodology and sample, our finding is similar to breast cancer survivors (for whom PTSD
prevalence of 5% to 6% has been reported).3,4 Our prevalence was adjusted upwards by
approximately 0.5% (from 6.9% to 7.4%) when accounting for nonresponse, suggesting that
similar and previous studies of cancer survivors may be under-reporting PTSD if they had
response patterns similar to those in our study.
Although the majority of survivors (61%) were not symptomatic for PTSD (ie, had no
symptom clusters), the prevalence in certain subgroups is cause for concern. For example,
nearly 16% of nonwhites qualified for a full PTSD diagnosis. The greater PTSD
symptomatology among nonwhite participants persists after adjustment for other
demographic and clinical factors, indicating that the discrepancy is not solely a result of
differences in education or disease status. A possible explanation for this disparity is that
individuals exposed to discrimination and prejudice may already be living with a heightened
sense of arousal and greater stress.
In two other subgroups, 15% of those with active NHL disease and 12% of younger
survivors (< 50 years of age) met criteria for PTSD. Survivors with current disease may
experience daily reminders of their illness, such as pain, itchiness, and fever. In support of
this finding, Deimling et al24 found that current cancer-related symptoms were the strongest
predictor of hyperarousal in a study of 180 adult, long-term cancer survivors. However, it is
worth noting that results from a multiple regression that excluded individuals with active
disease in our sample were substantively the same. Regarding age, Kornblith et al7 suggest
that younger survivors have less experience than their older counterparts in dealing with
medical crises and life threats, thereby feeling more distressed overall. Furthermore, they
may already be faced with more challenges at this earlier stage in the life cycle; for example,
younger survivors had significantly more cancer-related employment and insurance issues
than did their older counterparts (mean, 1.7 v 0.9 issues, respectively; P < .001), which was
largely attributable to the higher employment rate (75.8% v 31.7%, respectively). In addition
to increasing age being a protective factor for PTSD, the passage of time seems to mitigate
the impact of a cancer diagnosis and treatment. Perhaps least surprising was the finding that
other health-related stressors (ie, comorbidities) were predictive of PTSD symptomatology.
It is encouraging to consider that the psychosocial factors related to PTSD are potentially
modifiable. For example, cognitive behavioral and prolonged exposure techniques have
been shown to be effective in reducing or eliminating PTSD symptoms in other traumatized
populations, such as survivors of sexual assault,25 but the efficacy of psychosocial
treatments on cancer-related PTSD is just beginning to be examined.26 Interventions that
combine therapeutic approaches (eg, cognitive behavioral therapy, support groups) may be
desirable because we found social support to be correlated most strongly with avoidance
symptoms (r = −0.41, P < .001) and negative appraisals most related to re-experiencing
symptoms (r = 0.36, P < .001).
This study has some limitations, including the absence of a comparison group, a cross-
sectional study design, and inclusion only of patients treated at two large comprehensive
cancer centers. Without a comparison group, it is difficult to determine whether these NHL
survivors had more or less PTSD symptomatology than a similar group of people who never
had NHL. However, the markedly higher PTSD prevalence in our sample compared with
general population estimates suggests that NHL survivors have elevated PTSD
symptomatology, supporting the need to address it.
The cross-sectional design prevents determination of whether PTSD symptomatology or
certain risk factors (eg, low social support) occurred first. However, it is reasonable to
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assume that many of the risk factors (eg, nonwhite race, less education) preceded the PTSD.
Furthermore, this limitation should not affect the prevalence estimates except to the extent
that the sample is a mix of individuals at different places in their course of survivorship.
Finally, the inclusion of patients from only two large comprehensive cancer centers may
limit the generalizability of our results to survivors living in other regions and treated at
smaller hospitals. However, our demographic profile closely mirrors that of the national
population of NHL survivors, thereby strengthening the robustness and generalizability of
our prevalence estimates. Study strengths include a high response rate (74%), adjustment for
nonresponse, sophisticated and appropriate methodology for accounting for missing data,
two methods (linear and logistic regression) for identifying PTSD risk factors, and a
balanced sex ratio.
In closing, although the majority of survivors did not exhibit symptoms of PTSD, the impact
of diagnosis and treatment for cancer persists for many, such as having physical reactions to
reminders (trouble breathing or sweating), difficulties in concentration and sleep,
detachment from others, and avoiding medical care. Identification of those at risk (eg,
nonwhite, less education) early in the survivorship trajectory could promote screening and
treatment to minimize PTSD symptomatology.
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Conceptual model of cancer-related post-traumatic stress disorder (PTSD).
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Table 1
Characteristics of the Study Sample
Characteristic No. of Patients(N = 886) %
Demographics
 Sex
  Male 435 49.1
  Female 451 50.9
Race
 White 758 85.5
 African American 91 10.3
 Multiple race 30 3.4
 Other 7 0.8
Ethnicity
 Non-Hispanic 873 98.5
 Hispanic 13 1.5
Income level
 < $30,000 225 25.4
 $30,000-$59,999 239 27.0
 $60,000-$89,999 139 15.7
 ≥ $90,000 189 21.3
 Unknown 94 10.6
Education
 High school or less 250 28.2
 Some college or trade school 277 31.3
 College degree 199 22.5
 Postgraduate 138 15.6
 Unknown 22 2.4
Marital status
 Married 648 73.1
 Living with partner 24 2.7
 Widowed 90 10.2
 Separated/divorced 48 5.4
 Single 67 7.6
 Unknown 9 1.0
Employment status
 Retired 477 53.8
 Employed 350 39.5
 Unemployed 46 5.2
 Unknown 13 1.5
Age at enrollment, years
 Mean 62.9
 SD 13.5
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Characteristic No. of Patients(N = 886) %
 Range 25-92
 25-49 157 17.7
 50-64 323 36.5
 65-79 315 35.6
 ≥ 80 91 10.2
Histology of NHL
 Indolent 445 50.2
 Aggressive 391 44.2
 Unknown 50 5.6
Stage at diagnosis of NHL
 Stage I 247 27.9
 Stage II 159 17.9
 Stage III 146 16.5
 Stage IV 214 24.2
 Unknown 120 13.5
Types of treatment
 Mean, No. 2.1
 SD, No. 1.1
 No treatment 45 5.1
 Surgery 248 28.0
 Radiation therapy 418 47.1
 Chemotherapy 692 78.1
 Bone marrow/stem-cell transplantation 132 14.9
 Biologic therapy 261 29.5
 Other therapy 104 11.7
Current treatment status
 Not in treatment 752 84.9
 Receiving treatment 117 13.2
 Unknown 17 1.9
Disease status
 In remission or cured 680 76.7
 Not in remission 109 12.3
 Unknown 97 11.0
No. of recurrences
 0 562 63.4
 ≥ 1 293 33.1
 Unknown 31 3.5
No. of NHL-related visits
 0 172 19.4
 1-2 126 14.2
 3-4 138 15.6
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Characteristic No. of Patients(N = 886) %
 5-6 131 14.8
 7-10 90 10.2
 11-20 86 9.7
 > 20 113 12.8
 Unknown 30 3.4
Site of treatment
 Duke University 750 84.7
 UNC 136 15.3




 19-49 370 41.8
 50-64 337 38.0
 65-79 168 19.0





 2-4 219 24.7
 5-9 335 37.8
 10-14 150 16.9
 15-19 88 9.9
 ≥ 20 94 10.6
Clinical characteristics
 Secondary cancer(s)
  Yes 120 13.5
  No 752 84.9
  Unknown 14 1.6
 Comorbidities, No.
  Mean 2.9
  SD 2.1
  0 97 10.9
  1-2 326 36.8
  3-5 341 38.5
  6-8 95 10.7
  ≥ 9 12 1.4
  Unknown 15 1.7
 Years since last physical examination
  <1 year 480 54.2
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Characteristic No. of Patients(N = 886) %
  1-2 years 186 21.0
  3-4 years 71 8.0
  ≥ 5 years 128 14.4
  Unknown 21 2.4
Psychosocial
 Social support
  Mean 83.1
  SD 16.4
  Range 20-100
 Appraisal of life threat and treatment
   intensity
  Mean 19.3
  SD 6.0
  Range 6-30
 Employment and insurance issues
   related to cancer
  Mean 1.1
  SD 2.1
  Range 0-17
Abbreviations: SD, standard deviation; NHL, non-Hodgkin’s lymphoma; UNC, University of North Carolina.
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Table 2




Indicator of PTSD* % 95% CI % 95% CI
Score ≥ 44 6.9 5.2 to 8.6 7.4 5.6 to 9.1
3 Symptom clusters 7.6 5.8 to 9.4 7.9 6.1 to 9.7
2 Symptom clusters 8.9 7.0 to 10.8 9.1 7.2 to 11.0
1 Symptom cluster 22.2 19.5 to 25.0 22.3 19.5 to 25.0
No symptom clusters 61.3 58.1 to 64.5 60.7 57.5 to 64.0
Abbreviation: PTSD, post-traumatic stress disorder.
*
Based on the PTSD Checklist–Civilian Version (PCL-C). Symptom clusters include ≥ three avoidance symptoms, ≥ two arousal symptoms, and ≥
one re-experiencing symptom. All three clusters constitute full PTSD.
†
Adjusted for current age, age at diagnosis, and race.
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